Infectious Disease Therapeutics Market Trends

Infectious Disease Therapeutics Market size was valued at USD 119.86 Billion in 2023 and is poised to grow from USD 124.93 Billion in 2024 to USD 174.03 Billion by 2032, growing at a CAGR of 4.23% during the forecast period (2025-2032).

Global infectious disease therapeutics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Gilead Sciences ', 'GlaxoSmithKline (GSK) ', 'F. Hoffmann-La Roche Ltd ', 'Merck & Co., Inc. ', 'Pfizer Inc. ', 'Novartis AG ', 'Johnson & Johnson (Janssen Pharmaceuticals) ', 'BioCryst Pharmaceuticals Inc. ', 'Boehringer Ingelheim GmbH ', 'AbbVie Inc. ', 'Sanofi ', 'AstraZeneca ', 'Bristol-Myers Squibb (BMS) ', 'Moderna, Inc. ', 'Regeneron Pharmaceuticals ', 'Vertex Pharmaceuticals ', 'Vir Biotechnology, Inc. ', 'Eli Lilly and Company ', 'Amgen Inc.'

Increased spending to enhance the penetration rate of infectious disease treatments, rising strategies to raise awareness about treatments and diagnosis of these conditions, and increased clinical trial research for the development of new drugs may drive the growth of global infectious disease therapeutics market over the forecast period.

Increasing prevalence of malaria disease in developing and underdeveloped countries including India, Africa, and other Southeast Asian countries, as well as increased research and development activities by key manufacturers and health care organisations, are all contributing to market development.

North America held the largest global infectious disease therapeutics market share in 2021 due to the region's growing rate of infectious diseases. This region's large geriatric population has emerged as a significant growth factor for the market during the forecast period. People's increased disposable income has also become an important growth factor. The government's provision of advanced health-care facilities in the form of reimbursement policies has greatly aided market growth. Moreover, the existence of key manufacturers in the United States, as well as an increase in clinical trials for the introduction of new treatment drugs, are estimated to generate to this region's large market share.